查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
流感疫苗的全球市場的評估:各疫苗類型，各流感類型，各配方，各技術，各年齡層，各給藥途徑，各流通管道，各地區，機會，預測(2016年～2030年)
市場調查報告書
商品編碼
1301866

流感疫苗的全球市場的評估:各疫苗類型，各流感類型，各配方，各技術，各年齡層，各給藥途徑，各流通管道，各地區，機會，預測(2016年～2030年)

Influenza Vaccine Market Assessment, By Vaccine Type, By Type of Influenza, By Formulation, By Technology, By Age group, By Route of Administration, By Distribution Channel, By Region, By Opportunities and Forecast, 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 120 Pages | 商品交期: 3-5個工作天內

價格

全球流感疫苗市場規模預計將從2022年的80.2億美元增至2030年的117.8億美元，2023-2030年預測期間複合年增長率為4.92%。市場增長驅動因素包括流感高流行、政府對疫苗接種計劃的興趣增加、新開發的疫苗以及疫苗接種管理的技術進步等。

本報告提供全球流感疫苗市場相關調查分析，提供市場規模與預測，市場動態，主要企業的形勢及預測等資訊。

目錄

第1章 調查手法

第2章 計劃的範圍和定義

第3章 全球流感疫苗市場上COVID-19的影響

第4章 摘要整理

第5章 全球流感疫苗市場預測(2016年～2030年)

  • 市場規模與預測
    • 金額
    • 數量
  • 各疫苗類型
    • 不活化流感疫苗
    • 弱毒生流感疫苗
  • 各流感類型
    • 季節性
    • 大流行病
  • 各配方
    • 3價
    • 4價
  • 各技術
    • 蛋為基礎的
    • 細胞培養
    • 重組
  • 各年齡層
    • 兒童
    • 成人
  • 各給藥途徑
    • 肌肉注射
    • 點鼻子
  • 各流通管道
    • 醫院
    • 零售藥局
    • 政府的供應商
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東·非洲
  • 市場佔有率:各企業(2022年)

第6章 全球流感疫苗市場預測:各地區(2016年～2030年)

  • 北美
    • 不同類別的
    • 各流感類型
    • 各配方
    • 各技術
    • 各年齡層
    • 各給藥途徑
    • 各流通管道
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 越南
    • 韓國
    • 印尼
    • 菲律賓
  • 中東·非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第7章 市場製圖(2022年)

  • 各疫苗類型
  • 各流感類型
  • 各配方
  • 各技術
  • 各年齡層
  • 各給藥途徑
  • 各流通管道

第8章 宏觀環境和產業結構

  • 供需的分析
  • 進出口的分析
  • 價值鏈分析
  • PESTEL分析
  • 波特的五力分析

第9章 市場動態

  • 成長促進因素
  • 阻礙成長的要素(課題，阻礙因素)

第10章 法律規範和革新

  • 臨床試驗
  • 專利的形勢
  • 法規當局的認證
  • 革新/最新技術

第11章 主要企業形勢

  • 市場領導者前五名公司的競爭矩陣
  • 市場領導者前五名公司的市場收益分析(2022年)
  • 合併和收購/合資企業(如果相符)
  • SWOT分析(市場5參與企業)
  • 專利分析(如果相符)

第12章 價格分析

第13章 案例研究

第14章 主要企業預測

  • Sanofi Pasteur Inc.
  • GlaxoSmithKline PLC.
  • AstraZeneca PLC.
  • Abbott Healthcare Pvt Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Biken Co., Ltd.
  • Gamma Vaccines Pty Ltd.
  • CSL Limited.
  • Biodeme Ltd.
  • Sinovac Biotech Ltd.
  • Viatris Inc.

第15章 策略性推薦事項

第16章 關於本公司·免責聲明

Product Code: MX10177

Global Influenza Vaccine Market size was valued at USD 8.02 billion in 2022 which is expected to reach USD 11.78 billion in 2030 growing with a CAGR of 4.92% for the forecast period between 2023 and 2030. The drivers fuelling the growth of the worldwide influenza vaccine market include the high prevalence of influenza, increased government attention on immunization programmes, newly developed vaccines, and technological advancements in vaccine administration. The influenza epidemics are responsible for 2,90,000 to 6,50,000 respiratory deaths and 3 to 5 million cases of severe illness globally each year. The annual global attack rate for influenza is estimated to be 5-10% in adults and 20-30% in children. The elderly, expectant mothers, small children, and those with underlying medical issues are the groups that are highly susceptible to flu.

Twice a year, new flu vaccines are manufactured for the winter season in each hemisphere. This frequency is necessary due to the rapid mutation of the virus and changes in circulation patterns between consecutive winter seasons, which causes the effectiveness of previous vaccinations to diminish. Owing to the mutated new strains of influenza in circulation, particularly in northern and southern hemispheres, numerous seasonal influenza vaccines are reformulated each year. Hence, despite the immunity developed in patients due to older generation of vaccines, patients are required to vaccinated with reformulated versions each year to enhance immune response, thereby contributing to the demand for new reformulated vaccines and market growth.

The best method of preventing illness and serious consequences brought on by influenza viruses is vaccination. To create a unified strategy for the development of influenza vaccines, including their efficient use and distribution, production, testing, and regulatory control, World Health Organization (WHO) has been working with scientists and policymakers on a worldwide scale for more than 50 years.

Increasing Demand from Developing Countries

According to WHO, developing nations account for 99% of lower respiratory tract infection-related mortality in children under the age of five. Seasonal influenza can have a significant direct or indirect negative impact on both health and the economy. It can cause high rates of absence from work, productivity loss, and a heavy demand on healthcare systems, which can affect hospital capacity and medical expenditures. Many low and middle-income countries (LICs and MICs) lack accurate statistics on the disease burden caused by seasonal influenza, even though research indicates that these nations are like ly to have the largest burden of influenza among children and other populations at risk.

For instance, after receiving market authorization for the trivalent seasonal influenza vaccine developed by the Serbian Institute of Virol ogy, Vaccines and Sera- Torlak in August 2020, Serbia's efforts to establish and maintain domestic vaccine production has helped in ensuring the nation has a reliable and independent supply of influenza vaccines.

Development of New Vaccines Driving the Market

Although the strains of the currently available vaccines closely match the strains of the influenza virus in circulation, these vaccines usually provide only 40%-60% protection, with considerably lower protection in years due to insufficient strain matching. Since the strains chosen for the vaccine are selected six months prior to the inception of the influenza season that they are meant to combat, it is challenging for global health experts to determine which strains would be the best match for the upcoming season. Better strain matching may be possible in the future owing to mRNA technology's adaptability and faster production. Further, in event of a pandemic, influenza or outbreak, mRNA technology can help in faster mass production of vaccinations as mRNA-based influenza vaccines need the virus' genetic makeup.

For instance, Pfizer, one of the w orld's premier biopharmaceutical companies, initiated phase 3 study of single dose m-RNA based influenza vaccine in September 2022. With only the genetic makeup of the viruses required, mRNA-based vaccinations can be produced more quickly and with greater flexibility, potentially improving strain matching and the efficacy of current flu vaccines.

Government Initiatives

Governments around the globe are taking several initiatives to ensure the widespread availability and administration of influenza vaccines. These efforts are aimed at protecting public health and minimizing the impact of seasonal flu outbreaks. Some of the notable initiatives being taken by governments are vaccine production and distribution, surveillance and monitoring, vaccination programs, R&D and public awareness campaigns.

For instance, on 24th April 2023, Australian Government's Department of Health and Aged Care, launched an 8-week public awareness campaign under the National Immunization Program (NIP) to help and educate the people about the serious consequences of influenza. It is crucial for those who are more likely to experience difficulties from the flu, such as pregnant women and their unborn children, kids between the ages of 6 months to 5 years, and members of first nations communities.

Recombinant Vaccines Offers Clinical Advantage for Geriatric Patients

The recombinant flu vaccine is among the top three vaccines recommended specifically for individuals aged 65 and above. This preference is due to the reason that these vaccines demonstrate higher efficacy compared to standard dose unadjuvanted flu vaccines in this age group. In the event of a pandemic or during scarcity of the eggs required to develop influenza viruses, the production proc edure for recombinant vaccines is quicker than that for vaccines based on eggs because it is not dependent on an egg supply. The choice of vaccine viruses that are adapted for growth in eggs does not impose any restrictions on recombinant method.

For instance, Flublok Quadrivalent, developed by Sanofi Pasteur Inc., a recombinant flu shot is available for the 2022-2023 influenza season. It is recommended for active immunization against illness brought on by the type B and influenza A subtype viruses and can be used by those who are at least 18 years old.

Increasing Adoption of Inactivated Influenza Vaccines

Inactivated influenza vaccine is crucial in managing the spread of flu virus. These vaccines are made from dead strains of flu virus and are considered highly effective. One of the most important benefits of this vaccine is the safety of the recipient's health. Since the virus strains used in the creation of this vaccine are dead, hence it is incapable of causing a flu infection.

This makes inactivated vaccines suitable for people at a higher risk of serious complications, such as pregnant women, people with compromised immune system and children. Each year , a trivalent influenza vaccine is developed based on the influenza viruses expected to be common during the upcoming flu season. This medication can be prepared for injection or intranasal use.

For instance, Fluarix (2022-2023 formula), developed by GSK, is a trivalent inactivated influenza vaccine. It is a synthetic vaccine consisting of three inactivated influenza viruses, two different influenza type A strains and one influenza type B strain.

Impact of COVID-19

As per UNICEF (United Nations International Children's Emergency Fund), the glo bal demand for influenza vaccine has increased due to the COVID-19 pandemic. To ensure that countries receive the influenza vaccines in a timely manner and in sufficient quantities, a supply document has been issued. This document addresses crucial concerns related to the vaccine production process, procurement and supply information. The delivery of medical services around the world was hampered by the COVID-19 pandemic. Due to the 2019-2020 seasonal flu in the Northern Hemisphere and COVID-19 in the Southern Hemisphere, there has been an increase in the occurrence of coinfections, which has resulted in worse outcomes and excess mortality. Influenza vaccination reduced the occurrence of COVID-19 cases, hospitalizations, admissions to critical care units, and COVID-19-related mortality. By reducing the burden of influenza disease and enhancing the distinction between influenza and COVID-19-two diseases with similar signs and symptoms-influenza vaccination can thereby reduce the demand on healthcare resources brought on by the COVID-19 pandemic.

Key Players Landscape and Outlook

Pharmaceutical companies are engaging in mergers and acquisitions, joint ventures, and extensive collaborations for the manufacturing of influenza vaccines. The dominant market players are aiming to combine their coronavirus vaccines with annual flu shots. Furthermore, executives representing various vaccine manufacturers have expressed their expectations of a gradual transformation of the COVID-19 vaccine market to resemble the industry dynamics observed in the flu vaccine sector.

In November 2022, Pfizer Inc. and BioN Tech SE announced the advancement of an mRNA-based combination vaccine candidate for influenza and COVID-19 to a Phase 1 trial with the aim to treat two serious respiratory diseases with a single vaccination.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of Covid-19 on Global Influenza Vaccine Market

4. Executive Summary

5. Global Influenza Vaccine Market Outlook, 2016-2030F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.1. By Type of Vaccine
    • 5.1.1. Inactivated Influenza Vaccine
    • 5.1.2. Live Attenuated Influenza Vaccine
  • 5.2. By Type of Influenza
    • 5.2.1. Seasonal
    • 5.2.2. Pandemic
  • 5.3. By Formulation
    • 5.3.1. Trivalent
      • 5.3.1.1. Standard Dose Unadjuvanted
      • 5.3.1.2. High Dose Unadjuvanted
      • 5.3.1.3. Adjuvanted
    • 5.3.2. Quadrivalent
      • 5.3.2.1. Standard Dose Unadjuvanted
      • 5.3.2.2. Unadjuvanted
  • 5.4. By Technology
    • 5.4.1. Egg-based
    • 5.4.2. Cell culture
    • 5.4.3. Recombinant
  • 5.5. By Age Group
    • 5.5.1. Paediatric
    • 5.5.2. Adult
  • 5.6. By Route of Administration
    • 5.6.1. Intra-muscular injection
    • 5.6.2. Nasal Spray
  • 5.7. By Distribution Channel
    • 5.7.1. Hospital
    • 5.7.2. Retail Pharmacies
    • 5.7.3. Government Suppliers
    • 5.7.4. Others
  • 5.8. By Region
    • 5.8.1. North America
    • 5.8.2. Europe
    • 5.8.3. South America
    • 5.8.4. Asia-Pacific
    • 5.8.5. Middle East and Africa
  • 5.9. By Company Market Share (%), 2022

6. Global Influenza Vaccine Market Outlook, By Region, 2016-2030F

  • 6.1. North America*
    • 6.1.1. By Category
      • 6.1.1.1. Inactivated Influenza Vaccine
      • 6.1.1.2. Live Attenuated Influenza Vaccine
    • 6.1.2. By Type of Influenza
      • 6.1.2.1. Seasonal
      • 6.1.2.2. Pandemic
    • 6.1.3. By Formulation
      • 6.1.3.1. Trivalent
      • 6.1.3.1.1. Standard Dose Unadjuvanted
      • 6.1.3.1.2. High Dose Unadjuvanted
      • 6.1.3.1.3. Adjuvanted
      • 6.1.3.2. Quadrivalent
      • 6.1.3.2.1. Standard Dose Unadjuvanted
      • 6.1.3.2.2. Unadjuvanted
    • 6.1.4. By Technology
      • 6.1.4.1. Egg-based
      • 6.1.4.2. Cell culture
      • 6.1.4.3. Recombinant
    • 6.1.5. By Age Group
      • 6.1.5.1. Paediatric
      • 6.1.5.2. Adult
    • 6.1.6. By Route of Administration
      • 6.1.6.1. Intra-muscular injection
      • 6.1.6.2. Nasal Spray
    • 6.1.7. By Distribution Channel
      • 6.1.7.1. Hospital
      • 6.1.7.2. Retail Pharmacies
      • 6.1.7.3. Government Suppliers
      • 6.1.7.4. Others
    • 6.1.8. United States*
      • 6.1.8.1. By Category
      • 6.1.8.1.1. Inactivated Influenza Vaccine
      • 6.1.8.1.2. Live Attenuated Influenza Vaccine
      • 6.1.8.1.3. Adjuvanted
      • 6.1.8.2. By Type of Influenza
      • 6.1.8.2.1. Seasonal
      • 6.1.8.2.2. Pandemic
      • 6.1.8.3. By Formulation
      • 6.1.8.3.1. Trivalent
      • 6.1.8.3.1.1. Standard Dose Adjuvanted
      • 6.1.8.3.1.2. High Dose Unadjuvanted
      • 6.1.8.3.1.3. Adjuvanted
      • 6.1.8.3.2. Quadrivalent
      • 6.1.8.3.2.1. Standard Dose Unadjuvanted
      • 6.1.8.3.2.2. Unadjuvanted
      • 6.1.8.4. By Technology
      • 6.1.8.4.1. Egg-based
      • 6.1.8.4.2. Cell culture
      • 6.1.8.4.3. Recombinant
      • 6.1.8.5. By Age Group
      • 6.1.8.5.1. Paediatric
      • 6.1.8.5.2. Adult
      • 6.1.8.6. By Route of Administration
      • 6.1.8.6.1. Intra-muscular injection
      • 6.1.8.6.2. Nasal spray
      • 6.1.8.7. By Distribution Channel
      • 6.1.8.7.1. Hospital
      • 6.1.8.7.2. Retail Pharmacies
      • 6.1.8.7.3. Government Suppliers
      • 6.1.8.7.4. Others
    • 6.1.9. Canada
    • 6.1.10. Mexico

All segments will be provided for all regions and countries covered

  • 6.2. Europe
    • 6.2.1 Germany
    • 6.2.2 France
    • 6.2.3 Italy
    • 6.2.4 United Kingdom
    • 6.2.5 Russia
    • 6.2.6 Netherlands
    • 6.2.7 Spain
    • 6.2.8 Turkey
    • 6.2.9 Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Type of Vaccine
  • 7.2. By Type of Influenza
  • 7.3. By Formulation
  • 7.4. By Technology
  • 7.5. By Age Group
  • 7.6. By Route of Administration
  • 7.7. By Distribution Channel

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis
  • 8.3. Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

  • 10.1 Clinical Trials
  • 10.2 Patent Landscape
  • 10.3 Regulatory Approvals
  • 10.4 Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Sanofi Pasteur Inc.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. GlaxoSmithKline PLC.
  • 14.3. AstraZeneca PLC.
  • 14.4. Abbott Healthcare Pvt Ltd.
  • 14.5. F. Hoffmann-La Roche Ltd.
  • 14.6. Biken Co., Ltd.
  • 14.7. Gamma Vaccines Pty Ltd.
  • 14.8. CSL Limited.
  • 14.9. Biodeme Ltd.
  • 14.10. Sinovac Biotech Ltd.
  • 14.11. Viatris Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 3. Global Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 4. Global Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 5. Global Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 6. Global Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 7. Global Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 8. Global Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 9. Global Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 10. Global Influenza Vaccine Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 11. North America Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 12. North America Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 13. North America Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 14. North America Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 15. North America Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 16. North America Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 17. North America Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 18. North America Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 19. North America Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 20. North America Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 21. United States Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 22. United States Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 23. United States Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 24. United States Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 25. United States Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 26. United States Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 27. United States Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 28. United States Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 29. United States Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 30. Canada Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 31. Canada Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 32. Canada Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 33. Canada Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 34. Canada Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 35. Canada Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 36. Canada Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 37. Canada Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 38. Canada Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 39. Mexico Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 40. Mexico Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 41. Mexico Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 42. Mexico Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 43. Mexico Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 44. Mexico Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 45. Mexico Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 46. Mexico Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 47. Mexico Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 48. Europe Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 49. Europe Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 50. Europe Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 51. Europe Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 52. Europe Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 53. Europe Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 54. Europe Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 55. Europe Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 56. Europe Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 57. Europe Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 58. Germany Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 59. Germany Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 60. Germany Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 61. Germany Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 62. Germany Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 63. Germany Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 64. Germany Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 65. Germany Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 66. Germany Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 67. France Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 68. France Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 69. France Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 70. France Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 71. France Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 72. France Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 73. France Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 74. France Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 75. France Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 76. Italy Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 77. Italy Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 78. Italy Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 79. Italy Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 80. Italy Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 81. Italy Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 82. Italy Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 83. Italy Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 84. Italy Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 85. United Kingdom Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 86. United Kingdom Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 87. United Kingdom Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 88. United Kingdom Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 89. United Kingdom Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 90. United Kingdom Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 91. United Kingdom Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 92. United Kingdom Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 93. United Kingdom Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 94. Russia Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 95. Russia Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 96. Russia Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 97. Russia Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 98. Russia Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 99. Russia Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 100. Russia Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 101. Russia Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 102. Russia Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 103. Netherlands Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 104. Netherlands Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 105. Netherlands Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 106. Netherlands Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 107. Netherlands Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 108. Netherlands Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 109. Netherlands Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 110. Netherlands Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 111. Netherlands Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 112. Spain Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 113. Spain Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 114. Spain Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 115. Spain Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 116. Spain Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 117. Spain Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 118. Spain Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 119. Spain Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 120. Spain Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 121. Turkey Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 122. Turkey Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 123. Turkey Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 124. Turkey Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 125. Turkey Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 126. Turkey Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 127. Turkey Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 128. Turkey Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 129. Turkey Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 130. Poland Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 131. Poland Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 132. Poland Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 133. Poland Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 134. Poland Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 135. Poland Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 136. Poland Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 137. Poland Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 138. Poland Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 139. South America Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 140. South America Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 141. South America Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 142. South America Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 143. South America Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 144. South America Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 145. South America Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 146. South America Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 147. South America Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 148. South America Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 149. Brazil Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 150. Brazil Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 151. Brazil Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 152. Brazil Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 153. Brazil Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 154. Brazil Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 155. Brazil Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 156. Brazil Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 157. Brazil Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 158. Argentina Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 159. Argentina Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 160. Argentina Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 161. Argentina Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 162. Argentina Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 163. Argentina Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 164. Argentina Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 165. Argentina Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 166. Argentina Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 167. Asia-Pacific Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 168. Asia-Pacific Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 169. Asia-Pacific Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 170. Asia-Pacific Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 171. Asia-Pacific Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 172. Asia-Pacific Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 173. Asia- Pacific Cream Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 174. Asia-Pacific Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030
  • Figure 175. Asia-Pacific Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 176. Asia-Pacific Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 177. India Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 178. India Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 179. India Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 180. India Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 181. India Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 182. India Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 183. India Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 184. India Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 185. India Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 186. China Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 187. China Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 188. China Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 189. China Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 190. China Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 191. China Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 192. China Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 193. China Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 194. China Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 195. Japan Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 196. Japan Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 197. Japan Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 198. Japan Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 199. Japan Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 200. Japan Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 201. Japan Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 202. Japan Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 203. Japan Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 204. Australia Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 205. Australia Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 206. Australia Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 207. Australia Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 208. Australia Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 209. Australia Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 210. Australia Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 211. Australia Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 212. Australia Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 213. Vietnam Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 214. Vietnam Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 215. Vietnam Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 216. Vietnam Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 217. Vietnam Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 218. Vietnam Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 219. Vietnam Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 220. Vietnam Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 221. Vietnam Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 222. South Korea Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 223. South Korea Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 224. South Korea Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 225. South Korea Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 226. South Korea Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 227. South Korea Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 228. South Korea Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 229. South Korea Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 230. South Korea Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 231. Indonesia Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 232. Indonesia Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 233. Indonesia Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 234. Indonesia Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 235. Indonesia Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 236. Indonesia Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 237. Indonesia Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 238. Indonesia Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 239. Indonesia Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 240. Philippines Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 241. Philippines Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 242. Philippines Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 243. Philippines Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 244. Philippines Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 245. Philippines Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 246. Philippines Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 247. Philippines Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 248. Philippines Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 249. Middle East & Africa Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 250. Middle East & Africa Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 251. Middle East & Africa Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 252. Middle East & Africa Influenza Vaccine Market Share, By Type of vaccine, In Units Thousand, 2016-2030F
  • Figure 253. Middle East & Africa Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 254. Middle East & Africa Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 255. Middle East & Africa Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 256. Middle East & Africa Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 257. Middle East & Africa Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 258. Middle East & Africa Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 259. Middle East & Africa Influenza Vaccine Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 260. Saudi Arabia Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 261. Saudi Arabia Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 262. Saudi Arabia Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 263. Saudi Arabia Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 264. Saudi Arabia Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 265. Saudi Arabia Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 266. Saudi Arabia Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 267. Saudi Arabia Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 268. Saudi Arabia Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 269. UAE Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 270. UAE Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 271. UAE Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 272. UAE Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 273. UAE Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 274. UAE Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 275. UAE Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 276. UAE Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 277. UAE Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 278. South Africa Influenza Vaccine Market, By Value, In USD Billion, 2016-2030F
  • Figure 279. South Africa Influenza Vaccine Market, By Volume, In Units Thousand, 2016-2030F
  • Figure 280. South Africa Influenza Vaccine Market Share, By Type of vaccine, In USD Billion, 2016-2030F
  • Figure 281. South Africa Influenza Vaccine Market Share, By Type of Influenza, In USD Billion, 2016-2030F
  • Figure 282. South Africa Influenza Vaccine Market Share, By Formulation, In USD Billion, 2016-2030F
  • Figure 283. South Africa Influenza Vaccine Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 284. South Africa Influenza Vaccine Market Share, By Age Group, In USD Billion, 2016-2030F
  • Figure 285. South Africa Influenza Vaccine Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 286. South Africa Influenza Vaccine Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 287. By Type of vaccine Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 288. By Type of Influenza Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 289. By Formulation Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 290. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 291. By Age Group Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 292. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 293. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 294. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022